Detalhe da pesquisa
1.
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 25(5): 626-635, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38697156
2.
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Future Oncol
; 19(34): 2277-2289, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37746835
3.
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
Lancet Gastroenterol Hepatol
; 2024 May 29.
Artigo
Inglês
| MEDLINE | ID: mdl-38823398